Accuray (NASDAQ:ARAY – Get Free Report) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.
Accuray Price Performance
Shares of NASDAQ ARAY opened at $1.83 on Friday. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62. The company has a market cap of $188.18 million, a PE ratio of -36.60 and a beta of 1.46. The business has a 50-day simple moving average of $2.15 and a two-hundred day simple moving average of $2.00. Accuray has a fifty-two week low of $1.40 and a fifty-two week high of $2.95.
Accuray (NASDAQ:ARAY – Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. As a group, equities analysts expect that Accuray will post 0.01 EPS for the current fiscal year.
Institutional Investors Weigh In On Accuray
Accuray Company Profile
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Read More
- Five stocks we like better than Accuray
- How to Profit From Value Investing
- How to Build the Ultimate Everything ETF Portfolio
- What is Short Interest? How to Use It
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.